In this randomized , double-blind study , @ Japanese treatment-naive patients received once-daily daclatasvir @ mg or @ mg or placebo , each combined with peginterferon alfa-@b / ribavirin ; @ prior null ( n = @ ) or partial ( n = @ ) responders received the same daclatasvir-containing regimens without a placebo arm .